Open Payments

ST. LUKES HOSPITAL OF DULUTH

Type
Teaching hospital
Where
DULUTH, MN
Medicare CCN
240047
Received
$189,558 in 94 records, 2019 ($10,751 general, $178,806 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2019General payment6$10,751
2019Research payment88$178,806

By company

CompanyRecordsAmountYears
AstraZeneca Pharmaceuticals LP6$52,1182019
CSL Behring18$37,2272019
Janssen Research & Development, LLC15$35,4712019
ABBVIE INC.24$24,2792019
Boston Scientific Corporation18$20,6982019
Bard Peripheral Vascular, Inc.2$9,2092019
Abbott Laboratories4$7,2602019
Merck Sharp & Dohme LLC3$1,2502019
Eli Lilly and Company1$1,0002019
Novartis Pharmaceuticals Corporation1$6002019
Stryker Corporation1$2902019
Linvatec Corporation1$1522019

By nature of payment

NatureRecordsAmount
Research payment88$178,806
Gift3$9,499
Space rental or facility fees (teaching hospital only)2$1,100
Grant1$152

Records

DateCompanyAmountNatureFormProductStudyYear
2019-12-31AstraZeneca Pharmaceuticals LP$1,873Research paymentIn-kind items and servicesIMFINZI Drug, OncologyA Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for t2019
2019-12-31Stryker Corporation$290GiftIn-kind items and servicesPROFORM Device, PATIENT CARE - PC2019
2019-12-31Linvatec Corporation$152GrantIn-kind items and servicesHALL POWER Device, ORTHOPEDIC SURGERY2019
2019-12-26ABBVIE INC.$250Research paymentCash or cash equivalentRinvoq Biological, ImmunologyM14-4652019
2019-12-19CSL Behring$500Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-12-17CSL Behring$2,000Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-12-17CSL Behring$500Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-12-10AstraZeneca Pharmaceuticals LP$12,468Research paymentCash or cash equivalentIMFINZI Drug, OncologyA Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for t2019
2019-12-02Boston Scientific Corporation$800Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTAPPRAISE ATP2019
2019-11-25ABBVIE INC.$2,731Research paymentCash or cash equivalentRinvoq Biological, ImmunologyM14-4652019
2019-11-21CSL Behring$500Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-11-19Janssen Research & Development, LLC$89Research paymentCash or cash equivalentA Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) 2019
2019-11-14AstraZeneca Pharmaceuticals LP$17,769Research paymentCash or cash equivalentIMFINZI Drug, OncologyA Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Ste2019
2019-11-12Janssen Research & Development, LLC$1,469Research paymentCash or cash equivalentA Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) 2019
2019-11-07CSL Behring$1,051Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-11-07CSL Behring$50Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-10-21Boston Scientific Corporation$2,780Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial ProductPREEMPT HF2019
2019-10-21Boston Scientific Corporation$500Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial ProductPREEMPT HF2019
2019-10-16Abbott Laboratories$1,900Research paymentCash or cash equivalentOptim ICD Device, Cardiac Arrhythmias and Heart FailureOptim Lead Insulation Material (OPTIMUM) Registry2019
2019-10-15CSL Behring$500Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-10-10CSL Behring$285Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-10-08ABBVIE INC.$500Research paymentCash or cash equivalentM14-0642019
2019-10-07ABBVIE INC.$320Research paymentCash or cash equivalentRinvoq Biological, ImmunologyM14-4652019
2019-10-03Janssen Research & Development, LLC$200Research paymentCash or cash equivalentA Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) 2019
2019-10-03Janssen Research & Development, LLC$130Research paymentCash or cash equivalentA Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) 2019
2019-09-17CSL Behring$1,546Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-09-17CSL Behring$50Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-09-16Boston Scientific Corporation$500Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTAPPRAISE ATP2019
2019-09-16Boston Scientific Corporation$79Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTAPPRAISE ATP2019
2019-09-09ABBVIE INC.$150Research paymentCash or cash equivalentRinvoq Biological, ImmunologyM14-4652019
2019-09-05CSL Behring$350Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-08-29ABBVIE INC.$3,233Research paymentCash or cash equivalentRinvoq Biological, ImmunologyM14-4652019
2019-08-19Boston Scientific Corporation$1,125Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial ProductPREEMPT HF2019
2019-08-19Boston Scientific Corporation$250Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial ProductPREEMPT HF2019
2019-08-13CSL Behring$10,745Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-08-13CSL Behring$400Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-08-01Janssen Research & Development, LLC$500Research paymentCash or cash equivalentA Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) 2019
2019-07-31Abbott Laboratories$2,800Research paymentCash or cash equivalentOptim ICD Device, Cardiac Arrhythmias and Heart FailureOptim Lead Insulation Material (OPTIMUM) Registry2019
2019-07-25CSL Behring$500Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-07-23Janssen Research & Development, LLC$1,975Research paymentCash or cash equivalentA Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) 2019
2019-07-18Abbott Laboratories$500Research paymentCash or cash equivalentOptim ICD Device, Cardiac Arrhythmias and Heart FailureOptim Lead Insulation Material (OPTIMUM) Registry2019
2019-07-17ABBVIE INC.$250Research paymentCash or cash equivalentM14-0642019
2019-07-16Merck Sharp & Dohme LLC$500Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, P2019
2019-07-15Boston Scientific Corporation$1,600Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial ProductPREEMPT HF2019
2019-07-03ABBVIE INC.$500Research paymentCash or cash equivalentM14-0642019
2019-07-02Merck Sharp & Dohme LLC$250Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, P2019
2019-06-25Janssen Research & Development, LLC$500Research paymentCash or cash equivalentA Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) 2019
2019-06-25ABBVIE INC.$500Research paymentCash or cash equivalentM14-4652019
2019-06-17Boston Scientific Corporation$800Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial ProductPREEMPT HF2019
2019-06-14Boston Scientific Corporation$924Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTAPPRAISE ATP2019
2019-06-11Merck Sharp & Dohme LLC$500Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, P2019
2019-05-29ABBVIE INC.$2,731Research paymentCash or cash equivalentM14-4652019
2019-05-28CSL Behring$1,000Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-05-20Boston Scientific Corporation$2,400Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial ProductPREEMPT HF2019
2019-05-16Janssen Research & Development, LLC$1,429Research paymentCash or cash equivalentA Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) 2019
2019-05-16Janssen Research & Development, LLC$800Research paymentCash or cash equivalentA Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) 2019
2019-05-16Janssen Research & Development, LLC$500Research paymentCash or cash equivalentA Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) 2019
2019-05-13ABBVIE INC.$1,879Research paymentCash or cash equivalentM14-4652019
2019-05-13ABBVIE INC.$460Research paymentCash or cash equivalentM14-4652019
2019-05-03ABBVIE INC.$400Research paymentCash or cash equivalentM14-4652019
2019-05-03ABBVIE INC.$250Research paymentCash or cash equivalentM14-4652019
2019-05-02Janssen Research & Development, LLC$699Research paymentCash or cash equivalentA Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) 2019
2019-04-30ABBVIE INC.$500Research paymentCash or cash equivalentM14-4652019
2019-04-30ABBVIE INC.$150Research paymentCash or cash equivalentM14-4652019
2019-04-17ABBVIE INC.$500Research paymentCash or cash equivalentM14-0642019
2019-04-10ABBVIE INC.$3,000Research paymentCash or cash equivalentM16-2922019
2019-04-10ABBVIE INC.$500Research paymentCash or cash equivalentM16-2922019
2019-04-05Bard Peripheral Vascular, Inc.$4,694GiftIn-kind items and services2019
2019-04-05Bard Peripheral Vascular, Inc.$4,515GiftIn-kind items and services2019
2019-04-04Janssen Research & Development, LLC$500Research paymentCash or cash equivalentA Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) 2019
2019-04-01Boston Scientific Corporation$800Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial ProductPREEMPT HF2019
2019-03-26Eli Lilly and Company$1,000Research paymentCash or cash equivalentA RANDOMIZED PHASE 2 TRIAL OF AM0010 IN COMBINATION WITH NIVOLUMAB VS. NIVOLUMAB ALONE AS SECOND-LINE THERAPY IN SUBJECT2019
2019-03-18Boston Scientific Corporation$800Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial ProductPREEMPT HF2019
2019-03-18Boston Scientific Corporation$79Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTAPPRAISE ATP2019
2019-03-15Novartis Pharmaceuticals Corporation$600Space rental or facility fees (teaching hospital only)Cash or cash equivalentENTRESTO Drug, CARDIOVASCULAR2019
2019-03-15ABBVIE INC.$500Research paymentCash or cash equivalentM14-0642019
2019-03-12ABBVIE INC.$906Research paymentCash or cash equivalentHumira Biological, ImmunologyM14-4652019
2019-02-28ABBVIE INC.$3,318Research paymentCash or cash equivalentHumira Biological, ImmunologyM14-4652019
2019-02-11AstraZeneca Pharmaceuticals LP$500Space rental or facility fees (teaching hospital only)Cash or cash equivalentBRILINTA Drug, Cardiovascular and Metabolism2019
2019-02-07Janssen Research & Development, LLC$7,803Research paymentCash or cash equivalentA Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) 2019
2019-02-04Boston Scientific Corporation$510Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTAPPRAISE ATP2019
2019-01-30Abbott Laboratories$2,060Research paymentCash or cash equivalentOptim ICD Device, Cardiac Arrhythmias and Heart FailureOptim Lead Insulation Material (OPTIMUM) Registry2019
2019-01-25ABBVIE INC.$500Research paymentCash or cash equivalentHumira Biological, ImmunologyM14-4652019
2019-01-24Janssen Research & Development, LLC$5,977Research paymentCash or cash equivalentA Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) 2019
2019-01-22CSL Behring$12,000Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-01-22AstraZeneca Pharmaceuticals LP$10,770Research paymentCash or cash equivalentBRILINTA Drug, Cardiovascular and MetabolismUpstream Ticagrelor Registry Study2019
2019-01-22Boston Scientific Corporation$250Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial ProductPREEMPT HF2019
2019-01-17Janssen Research & Development, LLC$12,900Research paymentCash or cash equivalentA Phase 3 study comparing daratumumab . Lenalidomide and dexamethasone (DRd) versus lenalidomide and Dexamethasone (Rd) 2019
2019-01-17CSL Behring$2,750Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-01-17CSL Behring$2,500Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-01-15AstraZeneca Pharmaceuticals LP$8,737Research paymentCash or cash equivalentBRILINTA Drug, Cardiovascular and MetabolismA Multinational Randomised Double Blind Placebo Controlled Trial to Evaluate the Effect of Ticagrelor 90 mg twice dai2019
2019-01-09ABBVIE INC.$250Research paymentCash or cash equivalentHumira Biological, ImmunologyM14-4652019
2019-01-07Boston Scientific Corporation$4,000Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial ProductPREEMPT HF2019
2019-01-07Boston Scientific Corporation$2,500Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial ProductPREEMPT HF2019

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

St. Louis CountyDuluth city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Duluth, MN, county St. Louis County, MN, state Minnesota; placed by its city name.

MeasurePlace (city or town)
Duluth, MN
County
St. Louis County, MN
State
Minnesota
Population B0100387,093200,1235,739,445
Population, 2020 census P186,697200,2315,706,494
Median age B0100235.241.238.8
Under 18 B0100117.6%18.6%22.9%
65 and over B0100117.3%21.4%17.3%
Households B1100137,44787,1152,307,955
Foreign born B050023.1%1.9%8.7%
Median household income B19013$68,807$70,069$89,062
Median family income B19113$102,608$95,686$113,993
Per capita income B19301$41,503$41,302$48,237
Poverty rate B1700116.8%13.2%9.3%
Unemployment rate B230254.7%4.6%4.1%
Civilian labor force B2302548,580102,2803,119,042
Mean commute (minutes) B0801317.319.922.7
Bachelor's degree or higher B1500344.0%33.6%39.4%
Housing units B2500139,978104,2632,545,030
Owner-occupied B2500359.4%71.2%72.2%
Renters B2500340.6%28.8%27.8%
Median home value B25077$242,700$221,400$329,300
Median gross rent B25064$1,087$1,013$1,280
White, not Hispanic B0300286.6%89.5%75.9%
Black B030022.7%1.6%6.9%
Hispanic or Latino B030022.6%1.9%6.4%
Asian B030021.7%1.0%5.1%
American Indian and Alaska Native B030021.3%1.5%0.7%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Duluth, MN.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.